Our partners

Home |
Careers |
Contact |
Subscription |
Site map |
Français |
Text size: A A A

Ambrilia has high regard for partnerships because they support and add-value to activities both inside and outside its value chain. Accordingly, the Company cultivates relationships with quality partners who are experts in their respective field, such as clinical development, manufacturing and commercialization. Ambrilia’s current partners are:

C2L (octreotide): Acromegaly and carcinoid tumors – Phase III

Licensing Partners: TEVA Europe (France, Germany, Benelux, Spain, Scandinavia), Archimedes Pharma (U.K.), Gerolymatos (Greece, Turkey and other countries), Kwidza Pharma (Austria), Omega (Canada, Egypt), Pharmis (Portugal, Brazil) and Shin Poong (Korea).

Manufacturing Partners and main Suppliers: Lakeshore Biomaterial, PolyPeptides